» Articles » PMID: 16055556

In Vivo Engineering of Organs: the Bone Bioreactor

Overview
Specialty Science
Date 2005 Aug 2
PMID 16055556
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Treatment of large defects requires the harvest of fresh living bone from the iliac crest. Harvest of this limited supply of bone is accompanied by extreme pain and morbidity. This has prompted the exploration of other alternatives to generate new bone using traditional principles of tissue engineering, wherein harvested cells are combined with porous scaffolds and stimulated with exogenous mitogens and morphogens in vitro and/or in vivo. We now show that large volumes of bone can be engineered in a predictable manner, without the need for cell transplantation and growth factor administration. The crux of the approach lies in the deliberate creation and manipulation of an artificial space (bioreactor) between the tibia and the periosteum, a mesenchymal layer rich in pluripotent cells, in such a way that the body's healing mechanism is leveraged in the engineering of neotissue. Using the "in vivo bioreactor" in New Zealand White rabbits, we have engineered bone that is biomechanically identical to native bone. The neobone formation followed predominantly an intramembraneous path, with woven bone matrix subsequently maturing into fully mineralized compact bone exhibiting all of the histological markers and mechanical properties of native bone. We harvested the bone after 6 weeks and transplanted it into contralateral tibial defects, resulting in complete integration after 6 weeks with no apparent morbidity at the donor site. Furthermore, in a proof-of-principle study, we have shown that by inhibiting angiogenesis and promoting a more hypoxic environment within the "in vivo bioreactor space," cartilage formation can be exclusively promoted.

Citing Articles

Biomechanical Forces in the Tissue Engineering and Regeneration of Shoulder, Hip, Knee, and Ankle Joints.

Lp M, Agrawal D J Biotechnol Biomed. 2023; 6(4):491-500.

PMID: 38037618 PMC: 10688570. DOI: 10.26502/jbb.2642-91280111.


Bioengineered human tissue regeneration and repair using endogenous stem cells.

Wei J, Baptista-Hon D, Wang Z, Li G, Herrler T, Dai C Cell Rep Med. 2023; 4(8):101156.

PMID: 37586324 PMC: 10439273. DOI: 10.1016/j.xcrm.2023.101156.


Ex Vivo Preservation of Ovine Periosteum Using a Perfusion Bioreactor System.

Xin H, Romanazzo S, Tomaskovic-Crook E, Mitchell T, Hung J, Wise S Cells. 2023; 12(13).

PMID: 37443758 PMC: 10340137. DOI: 10.3390/cells12131724.


Sulfated Polysaccharide Regulates the Homing of HSPCs in a BMP-2-Triggered In Vivo Osteo-Organoid.

Dai K, Zhang W, Deng S, Wang J, Liu C Adv Sci (Weinh). 2023; 10(24):e2301592.

PMID: 37357138 PMC: 10460842. DOI: 10.1002/advs.202301592.


Additive Manufacturing of Polymer/Bioactive Glass Scaffolds for Regenerative Medicine: A Review.

Martelli A, Bellucci D, Cannillo V Polymers (Basel). 2023; 15(11).

PMID: 37299270 PMC: 10255145. DOI: 10.3390/polym15112473.


References
1.
Meyers M, Gagliardi A, Flattmann G, Su J, Wang Y, Woltering E . Suramin analogs inhibit human angiogenesis in vitro. J Surg Res. 2000; 91(2):130-4. DOI: 10.1006/jsre.2000.5920. View

2.
Gross A . Cartilage resurfacing: filling defects. J Arthroplasty. 2003; 18(3 Suppl 1):14-7. DOI: 10.1054/arth.2003.50084. View

3.
Boden S . Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976). 2002; 27(16 Suppl 1):S26-31. DOI: 10.1097/00007632-200208151-00007. View

4.
Parfitt A, Drezner M, Glorieux F, Kanis J, MALLUCHE H, Meunier P . Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2(6):595-610. DOI: 10.1002/jbmr.5650020617. View

5.
Petite H, Viateau V, Bensaid W, Meunier A, de Pollak C, Bourguignon M . Tissue-engineered bone regeneration. Nat Biotechnol. 2000; 18(9):959-63. DOI: 10.1038/79449. View